NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 11/11/2025 at 14:30, 2 months 27 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes

NanoViricides Securities Purchase Agreement Registered Direct Offering Warrants Pharmaceutical Candidates
BRIEF

published on 11/10/2025 at 14:35, 2 months 28 days ago

NanoViricides obtient l'autorisation pour un essai de phase II du NV-387 dans le traitement de la MPox

NanoViricides NV-387 Essais Cliniques Mpox Médicament Antiviral
BRIEF

published on 11/10/2025 at 14:35, 2 months 28 days ago

NanoViricides Granted Approval for Phase II Trial of NV-387 for MPox Treatment

NanoViricides NV-387 Clinical Trials Antiviral Drug Mpox
PRESS RELEASE

published on 11/10/2025 at 14:30, 2 months 28 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug

NanoViricides NV-387 Phase II Clinical Trial Broad-spectrum Antiviral MPOX Treatment
BRIEF

published on 11/05/2025 at 14:35, 3 months 3 days ago

NanoViricides se prépare à une assemblée générale cruciale de ses actionnaires dans un contexte de préoccupations croissantes liées au MPox

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Mpox
BRIEF

published on 11/05/2025 at 14:35, 3 months 3 days ago

NanoViricides Prepares for Critical Shareholders Meeting Amidst Rising MPox Concerns

NanoViricides NV-387 Clinical Trials Antiviral Drugs Mpox
PRESS RELEASE

published on 11/05/2025 at 14:30, 3 months 3 days ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway

NV-387 Clinical Trials NanoViricides Inc. Annual Shareholders Meeting Mpox Clade I
BRIEF

published on 11/03/2025 at 14:35, 3 months 5 days ago

NanoViricides présentera ses produits à la conférence des investisseurs de Spartan Capital en 2025.

NanoViricides NV-387 Essais Cliniques Médicaments Antiviraux Conférence De La Capitale Spartiate
BRIEF

published on 11/03/2025 at 14:35, 3 months 5 days ago

NanoViricides to Present at Spartan Capital Investor Conference 2025

NanoViricides NV-387 Clinical Trials Antiviral Drugs Spartan Capital Conference
PRESS RELEASE

published on 11/03/2025 at 14:30, 3 months 5 days ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing

NanoViricides NV-387 Clinical Trial Antiviral Drug Spartan Capital Investor Conference

Accesswire

Published on 02/07/2026 at 01:00, 1 day 14 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 16 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 17 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 23 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 2 days 1 hour ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 18 hours 29 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 22 hours 54 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 23 hours 9 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 20 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 21 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 1 day 21 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 21 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 23 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 23 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 7 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE